Family · Pharmaceutical analytical standards
Alectinib
An ALK kinase inhibitor for ALK-positive non-small cell lung cancer: first approved in Japan in 2014, in the United States in 2015 and in Europe in 2017. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines, other impurities and synthesis intermediates.
Did you know?It reaches the brain well because it is not pumped out by P-glycoprotein, the pump that guards the blood-brain barrier: this is why it is also active against brain metastases.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
